The effects of combined treatment with a glucocorticoid receptor (GR) antagonist, Org 34850, and a selective serotonin reuptake inhibitor (SSRI), fluoxetine, were investigated on pre-and postsynaptic aspects of 5-HT neurotransmission. Rats were treated for 14 days with Org 34850 (15 mg per kg per day subcutaneously), fluoxetine (10 mg per kg per day intraperitoneally), or a combination of both drugs.
INTRODUCTION
Selective serotonin reuptake inhibitors (SSRIs) are widely used for the treatment of depression. Although effective in some patients, SSRI treatment does not always induce complete remission of depression and many patients have persistent symptoms despite apparently 'adequate' dosing (Boulenger, 2004) . Interestingly, the hypothalamic-pituitary-adrenal (HPA) axis has been shown in several recent studies to have an influence on patients' response to antidepressant treatment. Thus, Young et al (2004) reported that the therapeutic response to SSRIs was lower in patients with HPA axis abnormalities than in those with normal HPA axis function. In a more recent and larger scale study, Brouwer et al (2006) showed that hyperactivity of the HPA axis predicted poor treatment response. Conversely, it has been reported that the clinical efficacy of 'serotonergic' antidepressants (including SSRIs) is improved by coadministration of an inhibitor of glucocorticoid synthesis (Jahn et al, 2004) .
The molecular target of SSRI antidepressants is the 5-HT transporter (5-HTT), which they block competitively, preventing the reuptake of released 5-HT. In experimental animals, chronic administration of SSRIs has been shown to cause an elevation in extracellular 5-HT in the forebrain (Bosker et al, 1995; Dawson et al, 2000) . It is believed that the therapeutic efficacy of SSRIs is dependent upon this elevation of forebrain 5-HT. This contention is supported by data showing that acute depletion of tryptophan (the precursor of 5-HT) results in a rapid return of symptoms in euthymic patients treated for depression with SSRIs (Delgado et al, 1999 ). An elevation of forebrain 5-HT levels would, of course, be predicted to increase the activation of postsynaptic 5-HT receptors. Although the particular receptor subtypes involved in the antidepressant response have not been definitively identified, the 5-HT 1A receptor is thought to be important (Cowen, 2000; Celada et al, 2004) .
As the clinical antidepressant response to SSRIs appears to be both reliant on forebrain 5-HT and influenced by corticosteroids, we proposed that glucocorticoids may modulate the ability of SSRIs to elevate forebrain 5-HT. In line with this hypothesis, we found that flattening the diurnal corticosterone rhythm in rats attenuates the ability of a chronic SSRI to elevate cortical 5-HT (Gartside et al, 2003) . Importantly, recently we showed that blockade of glucocorticoid receptors (GRs) has the opposite effect, enhancing the ability of an SSRI to elevate forebrain 5-HT levels (Johnson et al, 2007) . The mechanism underlying the interaction between SSRIs and glucocorticoid signaling remains unknown. However, it is of note that 5-HT neurones in the dorsal and median raphe nuclei (DRN and MRN, respectively) express GRs (Harfstrand et al, 1986; Gartside et al, 2008) , which are intracellular transcription regulatory proteins. Thus, it is possible that alterations in glucocorticoid signalling lead to changes in levels of expression of particular proteins within 5-HT neurones, which ultimately influence extracellular 5-HT.
In the present study we investigated the molecular basis of the SSRI Â GR antagonist interaction. To this end, we examined the effects of chronic treatment with an SSRI (fluoxetine) and/or a GR antagonist (Org 34850) on the expression of 5-HTT in the raphe and various forebrain regions considered important in the pathophysiology of depression. We also examined the expression in the raphe of mRNAs that code for the 5-HTT, the 5-HT synthesis enzyme tryptophan hydroxylase (TPH), and the 5-HT 1A autoreceptor, as well as levels of 5-HT 1A autoreceptor protein. Finally, to examine the consequences of the previously reported changes in 5-HT levels, we determined expression of postsynaptic 5-HT 1A receptors in the forebrain.
MATERIALS AND METHODS

Animals
Male Hooded Lister rats (150-180 g) were purchased from Charles River, UK. They were housed in groups of three in standard caging under controlled conditions of light (lights on 0700, lights off 1900 hours) and humidity. Animals were allowed free access to standard rat chow (SDS, UK) and tap water, and allowed to acclimatize to the holding facility for at least 5 days before initiation of treatment. All experiments were carried out under the Animals (Scientific Procedures) Act 1986 in accordance with the 'Guide for the Care and Use of Laboratory Animals' promulgated by the National Institutes of Health. Animals were healthy throughout and treatment groups did not differ in weight at start or end of treatment.
Drug Treatments
Treatments were for 14 days using a 2 Â 2 factorial design. Animals received Org 34850 (15 mg per kg, s.c.) or its vehicle (30% dimethylsulfoxide: 70% polyethylene glycol) twice daily at approximately 0700 and 1800 hours. Concurrently animals also received fluoxetine (10 mg per kg, i.p.) or its vehicle (sterile water) once daily at approximately 0700 hours. This gave four treatment groups: vehicle/vehicle, Org/vehicle, vehicle/fluoxetine, and Org/ fluoxetine.
Brain Sections
On the 15th day between 0800 and 0830 hours, animals were rapidly decapitated. The brain was removed and snapfrozen on dry ice and stored at À801C. Coronal sections (12 mm) were cut on a cryostat, thaw-mounted onto gelatinized slides and stored at À801C. Sections were collected from the following brain regions (anteroposterior distance from bregma according to Paxinos and Watson, 1986) : midbrain (À8.0 to À7.6 mm), ventral hippocampus (À6.04 to À4.8 mm), dorsal hippocampus (À3.8 to À3.14 mm) and prefrontal cortex (PFC) ( + 2.2 to + 3.2 mm).
In Situ Hybridization Histochemistry
In situ hybridization histochemistry with oligonucleotide probes was used to determine levels of expression of mRNAs encoding 5-HTT, 5-HT 1A receptor and TPH in the DRN and MRN. Briefly, the sections were fixed and pretreated for in situ hybridization in a single batch using an established protocol (McQuade et al, 2004 Sussex, UK). The labelled oligonucleotide probe was added to each section in hybridization buffer (50% formamide, 4 Â standard saline citrate (SSC), 10% dextran sulfate, 5 Â Denhardt's, 200 mg/ml salmon sperm DNA, 100 mg/ml polyA, 25 mM sodium phosphate, 1 mM sodium pyrophosphate, and 5% dithiothreitol (Pei et al, 1995) . The sections were incubated overnight (at 381C (5-HTT), 301C (TPH2), and 271C (5-HT 1A )) in sealed boxes containing 50% formamide in 4 Â SSC. Sections were then washed three times (20 min) in 1 Â SSC at 581C and twice (60 min) at room temperature. After air-drying, the sections, together with [ 14 C] microscale calibration strips (Amersham), were exposed to Biomax Hyperfilm (Amersham) for (2-12 weeks) before automatic development using an Agfa curix compact plus daylight processor.
Binding Studies
Citalopram binding was adapted from established protocols (Romero et al, 1998; Hebert et al, 2001) . The slides were preincubated in Tris buffer pH 7.4 (Tris-HCl, 50 mM, NaCl 120 mM, KCl 5 mM) at room temperature for 30 min. Slides were then incubated for 2 h at room temperature in Tris buffer containing 1. (C Troakes, personal communication) . Slides were preincubated for 30 min at room temperature in Tris buffer pH 7.5 (Tris-HCl, 170 mM, CaCl 2 4 mM, ascorbic acid 0.01%, and pargyline (10 mM; to prevent metabolism of 5-HT)). Slides were then incubated at room temperature for 90 min in fresh Tris buffer containing 2 nM [ 3 H]8-OH-DPAT (Amersham; specific activity 229 Ci/mmol). Nonspecific binding was determined for two slides per area using 5-HT (1 mM) added to the incubation medium. The slides were then washed (2 Â 5 min) in ice-cold Tris buffer, dipped in distilled water, and air-dried.
Slides were secured inside an X-ray cassette and exposed to Biomax Hyperfilm together with a [ 
Statistics
Binding data were initially analysed by three-way analysis of variance (ANOVA) with brain region treated as a repeated measure and treatment 1 (Org 34850 or vehicle) and treatment 2 (fluoxetine or vehicle) as between-subjects factors. Subsequently individual two-way ANOVA on each brain region was used, with treatments 1 and 2 as betweengroups factors. Where significant interactions were found, post-hoc comparisons between individual treatment groups were made using t-test. To account for the multiple comparisons made, Bonferroni correction was applied with pp0.0045 for the [ In situ hybridization data were subject to two-way ANOVA and, where significant interactions were found, post-hoc t-test. (Figure 1a) . In all regions of the mPFC, treatment with Org 34850 caused a small decrease (o15%), whereas fluoxetine treatment caused a marked reduction (approximately 60%) in [
RESULTS
Expression of 5-HTT in the Forebrain and Midbrain
3 H]-citalopram binding. When fluoxetine and Org 34850 treatments were combined, [
3 H]-citalopram binding was even further reduced and in some animals was close to the limit of detection (Figure 2 ). Two-way ANOVA showed a significant effect of fluoxetine and a significant effect of Org 34850, but there was no significant interaction between the treatments (Table 1; Figure 3 ).
Dorsal hippocampus. In the dorsal hippocampus [
3 H]-citalopram binding was dense in Ammon's horn with the highest density in stratum oriens of CA2 at the apex of the horn. Much lower binding was seen in the dentate gyrus, which could not be anatomically discriminated (Figure 1b) . In Ammon's horn treatment with Org 34850 alone caused a very small increase in [ (Figure 5a ). Within the cortex, the distribution was laminar being lowest in superficial layers and highest in layers V and VI. In the mPFC binding was particularly dense in layer VI adjacent to the corpus callosum. There were no significant effects of Org 34850 or fluoxetine treatment on [ 
3 H]-8-OH-DPAT binding was dense in stratum oriens and stratum radiatum dendritic layers of Ammon's horn, but was much lower in the pyramidal cell layer (Figure 5b ). Binding in CA2 was markedly lower than in the adjacent CA1 and binding in CA3 was higher than in CA1. In the dentate gyrus, [ DRN and MRN (Figure 5d ). There were no 
DISCUSSION
Here we investigated the effects of chronic fluoxetine and Org 34850 treatment, alone and in combination, on the expression of mRNAs and proteins associated with pre-and postsynaptic aspects of 5-HT neurotransmission. Chronic fluoxetine treatment caused a striking decrease in [ 3 H]-citalopram binding (a measure of 5-HTT expression) in cortex and hippocampus, as well as in the raphe nuclei. Importantly, concurrent Org 34850 and fluoxetine treatment markedly enhanced this decrease in 5-HTT levels, whereas Org 34850 treatment alone caused only small (and in some cases opposing) effects on 5-HTT. There were no changes in the expression of mRNAs coding 5-HTT, TPH, or the 5-HT 1A receptor, suggesting these effects were not mediated through changes in gene transcription. Furthermore, there were no significant effects of any of the treatments on either 5-HT 1A autoreceptor or postsynaptic 5-HT 1A receptor levels (measured by [ 3 H]-8-OH-DPAT binding). Org 34850 is a steroid molecule (for structure see Bachmann et al, 2003) , which has highest affinity for the GR (pEC 50 ¼ 8.0) with 3-fold selectivity over progesterone receptors and more than 300-fold selectivity over MR (Organon Laboratories in-house data). Our results indicate that the ability of GR antagonists (including Org 34850) to augment the effect of an SSRI on forebrain 5-HT (Johnson et al, 2007) results from a widespread enhancement of the fluoxetine-induced downregulation of 5-HTT. This augmentation of extracellular 5-HT appears not to cause any marked change in forebrain 5-HT 1A receptor expression. Given the proposed importance of 5-HT 1A receptormediated transmission to the antidepressant response, these data indicate that co-administration of GR antagonists may effectively augment the antidepressant response to SSRI treatment.
Downregulation of the 5-HTT
Chronic fluoxetine treatment induced a marked reduction in 5-HTT expression. Several studies have reported that chronic administration of other SSRIs decreases the Bmax of 5-HTT binding (Pineyro et al, 1994; Benmansour et al, 1999 Benmansour et al, , 2002 Gould et al, 2006) . Moreover, in complete accord with the present findings, Durand et al (1999) demonstrated a marked decrease in [ 3 H]-citalopram binding following chronic treatment with fluoxetine. Although other reports suggest that chronic fluoxetine fails to decrease 5-HTT levels (Dewar et al, 1993; Gobbi et al, 1997; Hebert et al, 2001) , the low doses of fluoxetine and/or lengthy washout periods used may account for these discrepancies. In the present study we measured 5-HTT binding in brains taken around 24 h after the last of 14 daily injections of fluoxetine (at the same point as we had made our measures of 5-HT levels (Johnson et al, 2007) ), and our binding protocol included a room temperature wash step to remove any residual drug.
The principal finding of this study is Org 34850 treatment enhanced the downregulation of the 5-HTT induced by fluoxetine. In the PFC and raphe nuclei, Org 34850 had an additive effect with fluoxetine reducing 5-HTT more than either treatment alone. However, in the hippocampus Org 34850 alone had no effect or tended to increase 5-HTT but, when combined with fluoxetine, displayed a marked synergy reducing 5-HTT to very low levels. Downregulation of 5-HTT may have a very important role in the delayed emergence of the neurochemical and antidepressant effects of SSRIs. Thus, Benmansour and colleagues showed that the SSRI-induced decrease in 5-HTT has a much more marked effect on extracellular 5-HT than does the presence of the reuptake inhibitor itself (Benmansour et al, 2002) . Perhaps because during acute blockade, the dynamic competition between the reuptake inhibitor and the increasing levels of extracellular 5-HT limits the consequences whereas, following downregulation of the 5-HTT (ie a loss of 5-HTT protein from the membrane) no such competition can take place. Org 34850 in combination with fluoxetine leads to a greater downregulation of 5-HTT, and so might be expected to lead to a greater enhancement of extracellular 5-HT levels, than fluoxetine alone. Thus, the biochemical data presented here are consistent with in vivo microdialysis findings in which we observed that concurrent treatment with Org 34850 enhanced the effect of fluoxetine on extracellular 5-HT in the PFC (Johnson et al, 2007) . However, it is worth noting that although the present data showed Org 34850 alone caused a small reduction in 5-HTT in the PFC, this treatment failed to affect extracellular 5-HT levels. One explanation for this is that there is spare transporter capacity and so the modest reduction in 5-HTT induced by Org 34850 alone is of insufficient magnitude to elevate 5-HT levels.
In addition to providing a mechanistic explanation for our previous findings (Johnson et al, 2007) , the present data Table 1 for full details of statistical analysis.
suggest that the augmentation of the effect of an SSRI on 5-HT would not be confined to the PFC (where our microdialysis was performed) but would occur widely through the brain. Indeed, in both dorsal and ventral hippocampus we found evidence for a true synergy between fluoxetine and Org 34850, which would predict a synergistic interaction in respect of extracellular 5-HT levels.
The fact that GRs are transcription regulatory proteins raises the possibility that the effect of the GR antagonist might be mediated by changes in mRNA expression. GRs have been shown to be expressed in 5-HT neurones in both the DRN and MRN (Harfstrand et al, 1986) , thereby having the potential to regulate protein synthesis within 5-HT neurones. However, none of the treatments affected expression of 5-HTT mRNA in the raphe nuclei. Although the effect of GR antagonists on 5-HTT mRNA has not been previously studied, the lack of effect of fluoxetine is consistent with previous data showing that chronic treatment with the same dose of fluoxetine did not alter 5-HTT mRNA measured at 21 days (Neumaier et al, 1996; Le Poul et al, 2000) . TPH2 mRNA expression was also unaltered by any of the treatments, suggesting that the alterations in extracellular 5-HT following fluoxetine and its enhancement by GR antagonists (Johnson et al, 2007) does not arise from a transcriptional changes in the TPH2 gene.
5-HT 1A Autoreceptors
None of the treatments altered the mRNA coding the 5-HT 1A autoreceptor in the DRN or the 5-HT 1A protein in either DRN or MRN. We have previously found functional desensitization of the somatodendritic 5-HT 1A autoreceptor following chronic fluoxetine (Gartside et al, 2003; Johnson et al, 2007) . The present data indicate that this desensitization is not the result of a decrease in 5-HT 1A receptor gene transcription or protein levels. This concurs with previous studies reporting fluoxetine-induced desensitization in 5-HT 1A autoreceptor function without concomitant changes in receptor binding (Le Poul et al, 1995; Hanoun et al, 2004 ). Table 1 for full details of statistical analysis.
Postsynaptic 5-HT 1A Receptors
Postsynaptic 5-HT 1A receptors, in both hippocampus and PFC, have been hypothesized to be important in the antidepressant response (Cowen, 2000; Celada et al, 2004) . For this reason we examined the effect of chronic SSRI and Org 34850 treatment on the expression of this receptor. Neither Org 34850 nor fluoxetine significantly altered 8-OH-DPAT binding across all forebrain regions measured. The lack of effect of fluoxetine is in line with previous reports that chronic administration of SSRIs fails to alter 5-HT 1A receptor binding in forebrain (Li et al, 1993; Le Poul et al, 2000; Hensler, 2002) . Consistent with this, in depressed patients, postsynaptic 5-HT 1A receptor binding measured by positron emission tomography was recently reported to be unchanged by chronic SSRI treatment (Moses-Kolko et al, 2007) . The effects of chronic GR antagonist treatment on 5-HT 1A binding have not been examined previously, however, 5-HT 1A binding is reportedly unchanged in GR deficient mice compared to wild types (Meijer et al, 1997) . Crucially, in the present study we found that the combination of fluoxetine and Org 34850 also failed to alter 5-HT 1A receptor binding. This suggests that the marked increase in extracellular 5-HT that arises from combined SSRI and GR antagonist treatment (Johnson et al, 2007) does not lead to changes in the number of postsynaptic 5-HT 1A receptors.
Although 5-HT 1A receptor number was not decreased the treatments, it cannot be assumed that 5-HT 1A receptor function is unaltered. That said, much evidence suggests that chronic SSRI treatment does not affect postsynaptic 5-HT 1A receptor sensitivity (Dong et al, 1999; Le Poul et al, 2000; Li et al, 1997; Hensler, 2002) . Indeed, as chronic administration of direct 5-HT 1A receptor agonists has been shown not to alter 5-HT 1A receptor sensitivity in CA3 (Dong et al, 1997; Haddjeri et al, 1999) , one can conclude that these receptors are unresponsive to agonist-induced downregulation or desensitization. Thus, although the combined treatment with fluoxetine and Org 34850 causes a marked increase in extracellular 5-HT (Johnson et al, 2007) , we would predict that this would not alter 5-HT 1A receptor sensitivity.
Conclusion
In our previous study we found that co-treatment with GR antagonists enhanced the SSRI-induced increase in extracellular 5-HT in the PFC (Johnson et al, 2007) . Here we show that the mechanism underlying this interaction is an Table 1 for full details of statistical analysis.
augmentation by the GR antagonist of the fluoxetineinduced downregulation of 5-HTT. Moreover, this enhancement of transporter downregulation is widespread, suggesting that GR antagonists have the potential to enhance SSRI effects on extracellular 5-HT in many brain areas. We have also shown that combined GR antagonist/ SSRI treatment does not result in a decrease in 5-HT 1A receptor protein and have presented evidence that argues against there being a downstream functional desensitization of these receptors. Thus, we predict that the overall effect of co-administration of a GR antagonist and an SSRI will be a marked enhancement of forebrain 5-HT 1A receptormediated neurotransmission. It has been hypothesized that an antidepressant response arises from increased postsynaptic 5-HT 1A receptor-mediated transmission in the forebrain (Cowen, 2000; Celada et al, 2004) . Hence, our data indicate that co-administration of GR antagonists may effectively augment the antidepressant response to SSRI treatment.
